• Advertise
  • About us
  • Terms and Conditions
  • Contact us
Monday, July 14, 2025
Australian Times News
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
Australian Times News
No Result
View All Result
Home News

Did the UK outsmart the EU over AstraZeneca vaccines?

In the “vaccine spat” between the EU and the UK, the common perception is that the UK is winning. The UK health secretary, Matt Hancock, has said this is because his government secured a better contract with vaccine manufacturers, in particular with AstraZeneca, than the EU did.

The Conversation by The Conversation
01-04-2021 18:09
in News
Photo by Nick Fewings on Unsplash

Photo by Nick Fewings on Unsplash

Gareth Davies, Vrije Universiteit Amsterdam

In the “vaccine spat” between the EU and the UK, the common perception is that the UK is winning. The UK health secretary, Matt Hancock, has said this is because his government secured a better contract with vaccine manufacturers, in particular with AstraZeneca, than the EU did.

The EU produces far more vaccines than the UK, but it also exports far more, including to the UK, whereas no vaccines go the other way. In response to this imbalance, which is creating shortages in the EU while the UK is well supplied, the EU has threatened to block exports to countries with higher vaccination rates until its member states catch up.

To date, 80% of the vaccines administered in the UK, 26 million out of the 32 million total, have been imports, of which 5 million came from India, and 21 million, or two-thirds came from the EU.

Put differently: the UK which, based on these figures, would only have been able to vaccinate about 10%-18% of its population if it had to rely on domestic supply, is enjoying a massive vaccine bailout from its European neighbours.

Why would the EU be so generous? Hancock referred to the clauses in the UK’s vaccine supply contracts requiring vaccine producers to supply it preferentially: if there are production shortages, then the UK order must be fulfilled by diverting supplies from other customers. A failure to do so attracts fierce penalties.

As a result, the UK has had its orders fully met, whereas the EU suffered early shortfalls from Pfizer, and is now receiving less than a quarter of what it contracted for from AstraZeneca, which has experienced production problems.

AlsoRead...

The Broker who says ‘Yes’ when Banks say NO

The Broker who says ‘Yes’ when Banks say NO

8 July 2025
Leading with Trust: Why Quality still wins in the AI Era

Leading with Trust: Why Quality still wins in the AI Era

5 June 2025

The EU takes the view that if production disappoints, all customers should see a proportional reduction in deliveries. The UK view is that it has a right to preferential supply, because that is what the contract says. The UK government invested in the research, done at the University of Oxford, that powered the AstraZeneca vaccine, and the firm has its headquarters in Cambridge, England.

Which contract to choose?

As a matter of law, both the EU and the UK have a case. Both contracts contain a “best reasonable efforts” clause, which is intended to cover the situation where force majeure – a legal term for an event outside one’s control – makes full delivery impossible or unreasonably difficult.

But signing a preferential contract with someone else is not force majeure: it is just selling the same stuff twice. AstraZeneca’s EU obligations are not diminished by its promises to the UK. But if AstraZeneca had distributed the output of its four European plants equally between the EU and UK, as the EU would like, it would be violating the UK contract. It appears to have promised too much to too many people.

The question is why AstraZeneca chose to breach the EU contract rather than the UK one. This will be largely because the UK deal had much harsher penalties – the EU deal has no penalties beyond non-payment and requires informal negotiation rather than litigation when problems arise.

So the UK did not contract better in the sense that it has a right to the vaccines it is obtaining; under the law governing the EU contract it does not. Rather, it seems that the UK contracted better in the sole sense that its contract was more expensive to breach.

That is partly a product of different legal systems and their styles: European contracting parties tend to see contracts as a tool to build up trust and long-term relationships. Anglo-American legal culture tends to see contracts as a way to avoid needing trust at all. Some Europeans seem jealous of this UK fierceness. On the other hand, if everyone did it, it wouldn’t work: grabbing more for yourself can only pay off for a few.

A question of fairness

In a situation of global shortage, any vaccine that one country obtains is one that another has lost, which puts a particular responsibility on states with power, money, and vaccine production facilities to consider where doses should go. Should the spoils go to the strongest, or are there issues of fairness?

The US and UK have been consistent and clear in their commitment to helping themselves first. While both have made promises to help others, this will only come after they have met their own needs, and there is no evidence either country has yet exported anything at all.

The EU is probably the third largest producer of vaccines, after the US and China, but has exported 77 million doses of COVID-19 vaccines to numerous countries and to Covax, the vaccine scheme for developing countries, to which it is the largest supplier.

The western European vaccine-producing countries have also agreed to supply the rest of their production to the EU as a whole to be made available on a per capita basis to all member states. They are adopting a policy of sharing with non-producing countries globally, and with their neighbours, which of course means less for themselves.

This is seen as utter foolishness, and failure, by the UK government. Its measure of success is how much its gets for people in the UK.

On the other hand, the EU hopes to reach a herd immunity level of vaccination in the summer, probably only a month or two after the UK. It will have done so while showing some sense of global responsibility.

Gareth Davies, Professor of EU Law, Vrije Universiteit Amsterdam

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Tags: SB001
DMCA.com Protection Status

SUBSCRIBE to our NEWSLETTER

[mc4wp_form id=”2384248″]

Don't Miss

The Dating Wealth Gap Is Getting Wider: What You Should Know

by Fazila Olla-Logday
11 July 2025
Source: Pixabay
Lifestyle

The divide between wealth and romance is growing. As income inequality widens, financial status is playing a bigger role in...

Read more

The Broker who says ‘Yes’ when Banks say NO

by Pauline Torongo
8 July 2025
The Broker who says ‘Yes’ when Banks say NO
Business & Finance

When faced with constant loan rejection or last-minute withdrawals of support, Trelos Finance stands out as a solution.

Read more

Common Mistakes When Buying a Telescope — And How to Avoid Them

by Fazila Olla-Logday
1 July 2025
Common Mistakes When Buying a Telescope
Technology

You’ve spent hours scrolling through telescope specs online, dazzled by features and grand promises. The excitement builds—until your newly arrived...

Read more

From Portugal to Bali: Where Aussies Should Go for Your Next Coastal Holiday

by Fazila Olla-Logday
20 June 2025
Source: Flickr
Travel

Aussies, here is a guide to where you should go for your next coastal holiday.

Read more

Leading with Trust: Why Quality still wins in the AI Era

by Pauline Torongo
5 June 2025
Leading with Trust: Why Quality still wins in the AI Era
Business & Finance

If you're leading a software team today, you've likely noticed the shift: faster feature rollouts, routine automation, and AI taking...

Read more

How to Save on Airport Parking: Budget Tips Every Traveller Should Know

by Fazila Olla-Logday
3 June 2025
How to Save on Airport Parking
Travel

Saving money on airport parking can be a challenge,but here are some budget friendly tips to help you navigate.

Read more

Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

by Pauline Torongo
28 May 2025
Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin
Business & Finance

Bélanger-Martin’s ambitions stretch beyond redefining inflight comfort—they’re rooted in resurrecting the romance of supersonic travel with a modern twist.

Read more
Load More

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

  • About us
  • Write for Us
  • Advertise
  • Contact us
  • T&Cs, Privacy and GDPR
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status